PSNL Personalis Inc.

Biotech Analyst Ratings

Latest News

1. 04 May 2022 Personalis Reports First Quarter 2022 Financial Results

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022.

   First Quarter and Recent Highlights

   • Reported quarterly revenue of $15.2 million in the first quarter of 2022 compared with $20.9 million in the first quarter of 2021
     • Revenue from biopharma and other customers, excluding the VA MVP (as defined below), of $11.7 million in the first quarter of 2022 compared with $7.7 million in the first quarter of 2021, a 53% increase; revenue from biopharma and other customers includes revenue of $4.1 million from Natera in the first quarter of 2022; revenue from biopharma customers excluding Natera of $7.6 million for the first quarter of 2022…

   View Full Article
2. 28 April 2022 Personalis to Present at Upcoming Investor Conferences

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following investor conferences:

   • Bank of America 2022 Healthcare Conference
     Presenting on Wednesday, May 11, 2022 at 6:20 p.m. Eastern Time at the Encore Hotel in Las Vegas
     A live audio webcast and replay of the presentation may be accessed for 90 days on the "Investors" section of the company's website at: https://personalis.com/.

   • UBS Global Healthcare Conference 2022
     Presenting on Tuesday, May 24, 2022 at 3:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New York

   About Personalis

   Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies…

   View Full Article
3. 26 April 2022 Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

   Evaxion Biotech A/S (NASDAQ:EVAX) and Personalis (NASDAQ:PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion's personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion's proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.

   "We believe we have found the key to efficiently activating the immune system to combat cancer. With our core AI tool called PIONEER, we accurately predict the patient's most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those…

   View Full Article
4. 21 April 2022 Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company's objective to accelerate expansion into the clinical market.

   "We are excited to welcome James to the team as he brings more than 20 years of successful commercial experience in oncology molecular diagnostics," said John West, CEO and co-founder of Personalis. "James will lead our clinical commercial efforts to pursue business with health care systems and oncologists in the United States. His focus will include growing our clinical test volume as we also work to secure reimbursement for NeXT Dx™ this year…

   View Full Article
5. 20 April 2022 Personalis to Announce First Quarter 2022 Financial Results

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

   Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 3187833. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the…

   View Full Article